We have again been asked to give an update on current activities in our firm’s Mass Torts Section. Lawyers in the Section have been very busy and are handling cases in several states in both... Read more
The first federal Actos trial is underway in Lafayette, La., before Judge Rebecca Doherty. Following jury selection, which took place the week before, the trial started on Feb. 4 and was ong... Read more
The U.S. Food and Drug Administration (FDA) has launched an investigation into the safety of an AstraZeneca PLC diabetes drug after a recent study found that users of the medication were mor... Read more
The incretin-based therapies litigation is in full swing in the Federal District Court for the Southern District of California (San Diego). Byetta (Amylin / Eli Lilli), Januvia (Merck), Jan... Read more
We wrote last month on litigation involving Pfizer’s blockbuster cholesterol treatment Lipitor. A lawsuit has been filed against Pfizer by a Louisiana woman, alleging that she developed Type... Read more
Four popular diabetes drugs are rapidly gaining critical notoriety in the United States. Januvia (Merck), Janumet (Merck), Byetta (Amylin / Bristol-Myers Squibb) and Victoza (Norvo Nordisk)... Read more
Of all medications currently being sold in the United States, Lipitor is one of the most commonly used brand-name medications. This cholesterol lowering statin medication had generated an es... Read more
While there may not be quite as many Januvia cancer lawsuits as there are for a competing diabetes drug Actos, the stakes are still considerable for Merck, the manufacturer of sitagliptin (J... Read more
We wrote about the risk of diabetes for women in the July issue. Researchers at the University of Massachusetts Medical School in Worchester have studied data on more than 150,000 women in t... Read more
Lawyers in our Mass Torts Section have been heavily involved in the litigation involving Actos, the diabetes drug. In June 2011, the FDA warned the public that Actos usage for more than one... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.